实体器官移植中的生物标志物
Biomarkers in solid organ transplantation.
作者信息
van Gelder Teun
机构信息
Department of Hospital Pharmacy, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
Department of Internal Medicine, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
出版信息
Br J Clin Pharmacol. 2017 Dec;83(12):2602-2604. doi: 10.1111/bcp.13391. Epub 2017 Sep 9.
Abstract
Recipients of solid organs such as the kidney and heart are treated with standard immunosuppressive regimens, and personalized medicine has not yet reached the clinic for this patient population. Biomarkers potentially will allow treatment regimens to be adjusted, according to the needs of the individual patient. Biomarkers may reflect the degree of immunosuppression of the immune system, or they may reflect early damage to the transplanted organ.
摘要
接受肾脏和心脏等实体器官移植的患者采用标准免疫抑制方案进行治疗，个性化医疗尚未应用于这一患者群体。生物标志物可能会使治疗方案根据个体患者的需求进行调整。生物标志物可能反映免疫系统的免疫抑制程度，也可能反映移植器官的早期损伤。
相似文献
1
Biomarkers in solid organ transplantation.实体器官移植中的生物标志物
Br J Clin Pharmacol. 2017 Dec;83(12):2602-2604. doi: 10.1111/bcp.13391. Epub 2017 Sep 9.
2
Urinary miR-155-5p and CXCL10 as prognostic and predictive biomarkers of rejection, graft outcome and treatment response in kidney transplantation.尿液中的miR-155-5p和CXCL10作为肾移植排斥反应、移植结局及治疗反应的预后和预测生物标志物。
Br J Clin Pharmacol. 2017 Dec;83(12):2636-2650. doi: 10.1111/bcp.13399. Epub 2017 Sep 21.
3
Biomarkers for kidney transplant rejection.用于肾移植排斥反应的生物标志物。
Nat Rev Nephrol. 2014 Apr;10(4):215-25. doi: 10.1038/nrneph.2013.281. Epub 2014 Jan 21.
4
5
Pretransplant serum CXCL9 and CXCL10 levels fail to predict acute rejection in kidney transplant recipients receiving induction therapy.接受诱导治疗的肾移植受者移植前血清CXCL9和CXCL10水平无法预测急性排斥反应。
Transplantation. 2011 Apr 27;91(8):e59-61. doi: 10.1097/TP.0b013e318210de6b.
6
Clinical epigenetics and acute/chronic rejection in solid organ transplantation: An update.临床表观遗传学与实体器官移植中的急性/慢性排斥反应：最新进展
Transplant Rev (Orlando). 2021 Apr;35(2):100609. doi: 10.1016/j.trre.2021.100609. Epub 2021 Feb 21.
7
Immune function as predictor of infectious complications and clinical outcome in patients undergoing solid organ transplantation (the ImmuneMo:SOT study): a prospective non-interventional observational trial.免疫功能作为实体器官移植患者感染并发症和临床结局预测因素的研究（ImmuneMo:SOT 研究）：一项前瞻性非干预性观察性试验。
BMC Infect Dis. 2019 Jul 3;19(1):573. doi: 10.1186/s12879-019-4207-9.
8
Immune monitoring in renal transplantation: The search for biomarkers.肾移植中的免疫监测：生物标志物的探索。
Eur J Immunol. 2016 Dec;46(12):2695-2704. doi: 10.1002/eji.201545963.
9
Minimization of immunosuppressive therapy and immunological monitoring of kidney transplant recipients with long-term allograft survival.长期同种异体肾移植存活受者免疫抑制治疗的最小化及免疫监测
Transpl Immunol. 2008 Nov;20(1-2):3-5. doi: 10.1016/j.trim.2008.08.008. Epub 2008 Sep 4.
10
Noninvasive diagnosis of acute rejection of solid organ transplants.实体器官移植急性排斥反应的非侵入性诊断
Front Biosci. 2004 Jan 1;9:145-53. doi: 10.2741/1218.
引用本文的文献
1
Review: immunosuppression for the lung transplant patient.综述：肺移植患者的免疫抑制
J Thorac Dis. 2021 Nov;13(11):6628-6644. doi: 10.21037/jtd-2021-11.
2
The Evolution of Lung Transplant Immunosuppression.肺移植免疫抑制的演变。
Drugs. 2018 Jul;78(10):965-982. doi: 10.1007/s40265-018-0930-6.
本文引用的文献
1
Urinary miR-155-5p and CXCL10 as prognostic and predictive biomarkers of rejection, graft outcome and treatment response in kidney transplantation.尿液中的miR-155-5p和CXCL10作为肾移植排斥反应、移植结局及治疗反应的预后和预测生物标志物。
Br J Clin Pharmacol. 2017 Dec;83(12):2636-2650. doi: 10.1111/bcp.13399. Epub 2017 Sep 21.
2
Aging and the immune response to organ transplantation.衰老与器官移植的免疫反应。
J Clin Invest. 2017 Jun 30;127(7):2523-2529. doi: 10.1172/JCI90601. Epub 2017 May 15.
3
Cell-Free DNA and Active Rejection in Kidney Allografts.肾移植中的游离DNA与急性排斥反应
J Am Soc Nephrol. 2017 Jul;28(7):2221-2232. doi: 10.1681/ASN.2016091034. Epub 2017 Mar 9.
4
The pharmacokinetics and pharmacodynamics of mycophenolate mofetil in younger and elderly renal transplant recipients.霉酚酸酯在年轻和老年肾移植受者中的药代动力学和药效学。
Br J Clin Pharmacol. 2017 Apr;83(4):812-822. doi: 10.1111/bcp.13154. Epub 2016 Nov 30.
5
Target Enzyme Activity and Phosphorylation of Pathway Molecules As Specific Biomarkers in Transplantation.作为移植中特定生物标志物的靶酶活性及通路分子的磷酸化
Ther Drug Monit. 2016 Apr;38 Suppl 1:S43-9. doi: 10.1097/FTD.0000000000000288.
6
Barcelona Consensus on Biomarker-Based Immunosuppressive Drugs Management in Solid Organ Transplantation.《实体器官移植中基于生物标志物的免疫抑制药物管理巴塞罗那共识》
Ther Drug Monit. 2016 Apr;38 Suppl 1:S1-20. doi: 10.1097/FTD.0000000000000287.
7
Urinary chemokines CXCL9 and CXCL10 are noninvasive markers of renal allograft rejection and BK viral infection.尿趋化因子 CXCL9 和 CXCL10 是非侵入性的肾移植排斥反应和 BK 病毒感染的标志物。
Am J Transplant. 2011 Oct;11(10):2228-34. doi: 10.1111/j.1600-6143.2011.03680.x. Epub 2011 Aug 3.
8
Biomarkers of over-immunosuppression.免疫抑制过度的生物标志物。
Clin Pharmacol Ther. 2011 Aug;90(2):316-22. doi: 10.1038/clpt.2011.111. Epub 2011 Jun 29.
9
Current immunosuppressive treatment after kidney transplantation.肾移植后当前的免疫抑制治疗。
Expert Opin Pharmacother. 2011 Jun;12(8):1217-31. doi: 10.1517/14656566.2011.552428. Epub 2011 Feb 2.
10
Urinary CXCL9 and CXCL10 levels correlate with the extent of subclinical tubulitis.尿CXCL9和CXCL10水平与亚临床肾小管炎的程度相关。
Am J Transplant. 2009 Jun;9(6):1347-53. doi: 10.1111/j.1600-6143.2009.02645.x. Epub 2009 May 13.
Zotero 插件